How India Exports Metformin to the World

In the United States, metformin is approved through Abbreviated New Drug Applications (ANDAs), allowing generic manufacturers to market the drug upon demonstrating bioequivalence to the reference listed drug. The FDA's Orange Book lists numerous approved ANDAs for metformin, reflecting its established presence in the market. Recent approvals include [specific approval dates and numbers, if available]. Importantly, there are no current FDA import alerts for metformin, indicating compliance with regulatory standards. The substantial number of Indian exporters—528 active between 2022 and 2026—underscores India's significant role in supplying metformin to the U.S. market.

In the European Union, metformin requires marketing authorization from the European Medicines Agency (EMA) or national competent authorities. The EMA's centralized procedure facilitates approval across member states, ensuring consistent quality, safety, and efficacy standards. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of metformin, adhering to stringent GMP requirements. The presence of Indian exporters in these markets highlights the importance of maintaining compliance with EU and UK regulatory standards.

Metformin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in managing diabetes globally. The 24th edition of the list, published in September 2025, continues to feature metformin as a fundamental treatment option. Additionally, metformin is listed in the International Pharmacopoeia, which provides quality specifications for essential medicines, ensuring consistency in manufacturing and quality control processes worldwide. (who.int)

In India, metformin is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability; the latest ceiling price was set in [specific month and year]. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical exports.

Metformin's primary patents have long expired, leading to a competitive generic market. This has facilitated the entry of multiple manufacturers, including numerous Indian exporters, contributing to its widespread availability and affordability globally.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming metformin's inclusion due to its efficacy and safety profile. (who.int) In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, continuing to feature metformin as a fundamental treatment option. (who.int)

These developments reflect the ongoing recognition of metformin's importance in global health and the pharmaceutical industry's commitment to maintaining its availability and quality.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 70% of India's APIs are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities, as disruptions in Chinese manufacturing—due to environmental regulations, geopolitical tensions, or other factors—can lead to shortages and increased costs for Indian manufacturers.

In response, the Indian government launched the Production Linked Incentive (PLI) scheme in 2024, aiming to bolster domestic API and KSM production. By November 2024, two greenfield plants were inaugurated under this initiative to manufacture critical molecules like Penicillin G and Clavulanic Acid, which had not been produced domestically for over two decades. Despite these efforts, challenges such as higher production costs and infrastructure limitations persist, making it difficult for India to achieve self-sufficiency in API production.

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals that the top five Indian exporters account for 55.9% of Metformin exports, with GRANULES INDIA LIMITED alone contributing 32.7% ($152.5M USD). This high supplier concentration poses a significant risk; any operational disruptions within these key companies could severely impact global Metformin supply.

The PLI scheme, initiated in 2024, aims to mitigate such risks by encouraging diversification and increasing domestic production capacity. However, the scheme's effectiveness is challenged by factors like China's aggressive pricing strategies, which have seen API prices slashed by up to 50% in 2025, undermining India's self-sufficiency efforts. Additionally, infrastructural and regulatory hurdles continue to impede rapid scaling of domestic production.

Recent geopolitical events have further strained the Metformin supply chain. In February 2026, the closure of the Strait of Hormuz following US and Israeli military actions against Iran disrupted global shipping routes, leading to increased transit times and costs. This disruption has had a cascading effect on the pharmaceutical industry, including Metformin exports from India, as shipping delays and elevated fuel prices impact logistics and overall supply chain efficiency.

Additionally, tensions in the Red Sea and the Strait of Hormuz have heightened risks for commercial shipping, with reports of attacks on vessels and increased insurance premiums. These factors contribute to the volatility of global supply chains, affecting the timely delivery of pharmaceutical products.

• Diversify Supplier Base: Encourage partnerships with a broader range of API manufacturers to reduce dependency on a limited number of suppliers.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and invest in infrastructure to support domestic API and KSM manufacturing.

• Develop Alternative Shipping Routes: Explore and establish alternative logistics pathways to mitigate risks associated with geopolitical disruptions in key maritime chokepoints.

• Strengthen Regulatory Compliance: Ensure adherence to international quality standards to maintain market access and reduce the risk of export bans due to compliance issues.

• Monitor Geopolitical Developments: Establish a dedicated task force to continuously assess and respond to geopolitical events that may impact the pharmaceutical supply chain.

RISK_LEVEL: HIGH